All News

Phase 3 BOND-003 data published in Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.

Experts discuss why accurately recognizing CIS in patients with suspected NMIBC is essential to preventing disease progression, guiding surveillance, and expanding treatment and clinical trial opportunities.

Darlifarnib plus cabozantinib demonstrated encouraging antitumor activity with a manageable safety profile in patients with ccRCC, including both cabozantinib-naive and cabozantinib-exposed populations.

Joshua Halpern, MD, MS, reviews evidence supporting the accuracy of mail-in semen analysis and identifies patients who may benefit most from at-home testing.

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

In this episode, Jason Hafron, MD, explains how data-driven pathways and patient follow-up systems can improve quality and outcomes in urologic oncology.

Can Aydogdu, MD, highlights a study examining the utility of pre-surgical tumor-informed ctDNA to predict pathologic nodal status at radical cystectomy.

The PDUFA target action date is in the fourth quarter of 2026.

The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.

Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.

These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.

Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, discusses the clinical significance of the phase 3 PROTEUS trial and addresses concerns about the study's use of ADT in the control arm.

Amy Pearlman, MD, and Larry I. Lipshultz, MD, speak with Shane Kronstedt, MD, about research on the long-term reproductive and urologic effects of military exposures and how these findings may help improve care for veterans.

Experts discuss why CIS is frequently underrecognized, highlighting the subtle clinical and cystoscopic features of the disease and the importance of integrating multiple factors to improve detection.

This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.

Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG-naive NMIBC.

Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.

Kathryn H. Gessner, MD, PhD, discusses the current limitations in identifying appropriate candidates for bladder-preserving trimodal therapy, the promise of utDNA, and why shared decision-making remains essential.

A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of postureteroscopy health care utilization, with each 100-mm³ increase doubling event odds.

The Department of Defense will begin annual testosterone deficiency screening for service members aged 30 years and older.

Richard N. Schlussel, MD, discusses how advances in robotic surgery and artificial intelligence are expected to transform care in pediatric urology.

Jamie Michael, MD, highlights a study exploring the impact of MRI and genomics on "extreme" grade reclassification in men on active surveillance.

Dose interruption rather than discontinuation addresses most gemcitabine intravesical system (Inlexzo) adverse events, with designated champions supporting consistent patient management, according to Elizabeth Mobley, MD.

Elizabeth Mobley, MD, shares practical tips for counseling patients and managing adverse events during treatment with the gemcitabine intravesical system.

Proactive adverse event counseling and a specific hydration protocol are the primary tools for supporting patient retention through the gemcitabine intravesical system's (Inlexzo) extended treatment course, according to Mobley.

The phase 2 study is assessing whether an adaptive treatment approach can improve responses and enable treatment pauses for select patients.

University of Florida chief residents share practical advice for trainees on building mentorship networks, maintaining well-being, and navigating the personal and professional challenges of urology residency.

The pivotal phase 3 Himalayas-1 trial will evaluate rinzimetostat plus darolutamide vs with physician's choice of an ARPI or docetaxel.